Erectile dysfunction affects nearly 50% of men with type 2 diabetes over their lifetime. Weight loss consistently improves erectile function. GLP-1 medications cause significant weight loss. So GLP-1s should help erections, right?
Mostly yes — but with a wrinkle that showed up in 2026 data.
The Positive Evidence: Weight Loss Helps
A 2025 NIH review confirmed that GLP-1 medications in obese and overweight men increased total testosterone, optimized hormone levels, and improved erectile-function scores. This makes physiological sense: visceral fat is an estrogen factory (via aromatase conversion), and reducing it shifts the testosterone-to-estrogen ratio back toward normal.
The REWIND trial (dulaglutide) specifically examined erectile function and found improvements in a diabetic male population. Multiple meta-analyses of weight loss interventions confirm that losing 10–15% of body weight significantly improves IIEF scores (the standardized erectile function questionnaire).
The New Concern: A Modest Risk Signal
A 2026 target trial emulation published in EClinicalMedicine analyzed 4,910 GLP-1 users and 5,524 DPP4-inhibitor users — all men with type 2 diabetes. The finding:
The incidence rate was 35.2 per 1,000 person-years for GLP-1 users vs. 28.0 for DPP4i users. The association was robust across sensitivity analyses but attenuated after calibration for unmeasured confounders.
A separate FAERS database analysis found 182 GLP-1-related sexual adverse event reports including ED, decreased libido, and orgasmic disorders — predominantly in men aged 40–60 with type 2 diabetes.
How to Reconcile the Data
The most likely explanation: GLP-1s improve erectile function through weight loss (the dominant effect) but may have a minor direct pharmacological effect that slightly increases ED risk in some men — particularly those with type 2 diabetes and existing vascular damage.
For most men, the net effect is positive. The weight loss, improved cardiovascular health, and testosterone normalization outweigh the modest pharmacological signal. But if you notice changes in erectile function after starting a GLP-1, it's worth discussing with your provider rather than ignoring it.
Practical Recommendations
- Get baseline testosterone and IIEF scores before starting GLP-1 therapy. You can't track changes without a baseline.
- Monitor at 3 and 6 months. If erectile function worsens despite weight loss, it's likely not the weight — it may be the drug or an unrelated issue.
- Consider multi-vertical providers. Platforms like BiltRx and Care Bare Rx offer GLP-1s alongside ED treatment (sildenafil, tadalafil) under one roof — easier to address both simultaneously.
- Don't skip TRT evaluation. If testosterone doesn't normalize after 6 months of weight loss (the ENDO 2025 data showed normalization in 53→77% of men), TRT may be the next step.
Sources
- Tang H et al. "GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation." EClinicalMedicine. 2026.
- Noakes J et al. "GLP-1 receptor agonists and male sexual health." Int J Impot Res. 2026.
- FAERS database analysis. "Male sexual dysfunction associated with GLP-1 receptor agonists." 2025.
- Bajaj HS et al. "Erectile function in men with type 2 diabetes treated with dulaglutide." REWIND. Lancet Diabetes Endocrinol. 2021.
- Fox News/NIH review. "Weight-loss medications and sexual health." February 2026.